1. Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020;202:e36–e69.
2. Pérez ERF, Travis WD, Lynch DA, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest 2021;160:e97–e156.
3. 3. The Korean Academy of Tuberculosis and Respiratory Diseases. Interstitial lung disease (ILD) clinical practice guidelines (2023 1st revised) [Internet]. Seoul (KR): The Korean Academy of Tuberculosis and Respiratory Diseases, c2023 [cited 2024 Feb 1]. Available from: https://www.lungkorea.org/bbs/index.html?code=guide&category=&gubun=&page=1&number=13253&mode=view&keyfield=&key=
4. Girard M, Israël-Assayag E, Cormier Y. Impaired function of regulatory T-cells in hypersensitivity pneumonitis. Eur Respir J 2011;37:632–639.
5. Vasakova M, Selman M, Morell F, Sterclova M, MolinaMolina M, Raghu G. Hypersensitivity pneumonitis: current concepts of pathogenesis and potential targets for treatment. Am J Respir Crit Care Med 2019;200:301–308.
6. Camarena A, Juárez A, Mejía M, et al. Major histocompatibility complex and tumor necrosis factor-alpha polymorphisms in pigeon breeder's disease. Am J Respir Crit Care Med 2001;163:1528–1533.
12. Park MS. Diagnosis and treatment of hypersensitivity pneumonitis. J Korean Med Assoc 2009;52:49–58.
15. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004–1014.
16. Soumagne T, Dalphin JC. Current and emerging techniques for the diagnosis of hypersensitivity pneumonitis. Expert Rev Respir Med 2018;12:493–507.
17. Iftikhar IH, Alghothani L, Sardi A, Berkowitz D, Musani AI. Transbronchial lung cryobiopsy and video-assisted thoracoscopic lung biopsy in the diagnosis of diffuse parenchymal lung disease. A meta-analysis of diagnostic test accuracy. Ann Am Thorac Soc 2017;14:1197–1211.
18. Lynch DA. CT phenotypes in hypersensitivity pneumonitis. Chest 2019;155:655–656.
19. Barnett J, Molyneaux PL, Rawal B, et al. Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. Eur Respir J 2019;54:1900531.
20. Chami HA, Diaz-Mendoza J, Chua A, et al. Transbronchial biopsy and cryobiopsy in the diagnosis of hypersensitivity pneumonitis among patients with interstitial lung disease. Ann Am Thorac Soc 2021;18:148–161.
21. Alberti ML, Ruiz JMM, Fernández ME, et al. Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Pulmonology 2020;26:3–9.
22. Choe J, Chae EJ, Kim YJ, Do KH, Song JS, Song JW. Serial changes of CT findings in patients with chronic hypersensitivity pneumonitis: imaging trajectories and predictors of fibrotic progression and acute exacerbation. Eur Radiol 2021;31:3993–4003.
24. Lima MS, Coletta EN, Ferreira RG, et al. Subacute and chronic hypersensitivity pneumonitis: histopathological patterns and survival. Respir Med 2009;103:508–515.
25. De Sadeleer LJ, Hermans F, De Dycker E, et al. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur Respir J 2020;55:1901983.
26. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis. Eur Radiol 2017;27:3635–3646.
27. Gimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax 2018;73:391–392.
31. Ferreira M, Borie R, Crestani B, et al. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): a retrospective, multicentric, observational study. Respir Med 2020;172:106146.
32. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381:1718–1727.
33. Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020;8:453–460.
34. Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021;9:476–486.
35. Pérez ERF, Crooks JL, Lynch DA, et al. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax 2023;78:1097–1104.
38. Holland AE, Dowman LM, Hill CJ. Principles of rehabilitation and reactivation: interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement. Respiration 2015;89:89–99.
39. Wijsenbeek MS, Holland AE, Swigris JJ, Renzoni EA. Comprehensive supportive care for patients with fibrosing interstitial lung disease. Am J Respir Crit Care Med 2019;200:152–159.
40. Kern RM, Singer JP, Koth L, et al. Lung transplantation for hypersensitivity pneumonitis. Chest 2015;147:1558–1565.
41. Tomioka H, Miyazaki Y, Inoue Y, et al. Japanese clinical practice guide 2022 for hypersensitivity pneumonitis. Respir Investig 2024;62:16–43.